Kaftrim

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kaftrim

Property Description
Active Ingredients Sulphamethoxazole, Trimethoprim
Form Tablet, oral suspension, IV solution
Pharmacological Class Antibacterial (Antimicrobial Agent)
Common Use Treating bacterial infections
Origin Synthetic

What Type of Medicine is Kaftrim?

Kaftrim is a synthetic antibacterial agent that is fundamentally a fixed-dose combination product, known generically as Co-trimoxazole. This medicine belongs to the broad class of antimicrobial agents and is specifically engineered to target a wide spectrum of susceptible bacterial pathogens. Its established therapeutic value is recognized for its significance and efficacy in global public health settings. Kaftrim, as a trade name, contains the same active formulation used in other clinically recognized brands, such as Bactrim and Septra, demonstrating the dual-component approach.

Composition and Pharmaceutical Forms

The two active ingredients in Kaftrim are Sulphamethoxazole (a sulfonamide antibiotic) and Trimethoprim (a diaminopyrimidine inhibitor), which are combined in a specific ratio for simultaneous administration. This strategic pairing ensures a greater therapeutic effect than if either component were used alone, maximizing the potential to halt the infection. The medicine is clinically recognized for targeting key metabolic processes in bacterial cells. This combination creates a potent synergistic effect against bacterial enzymes. Kaftrim is supplied in various dosage forms, including tablets for oral use, an oral suspension (often preferred for pediatric patients), and a preparation for intravenous infusion.

How Does Kaftrim Target Bacterial Growth?

Kaftrim works by executing a sequential blockade against bacterial metabolism, specifically targeting the two-step process of folate synthesis that is vital for bacterial growth and replication. Sulphamethoxazole blocks the first step, while Trimethoprim blocks the second, effectively preventing the bacteria from creating the necessary building blocks for survival. This coordinated action results in a potent bactericidal effect and serves the general therapeutic purpose of arresting the proliferation of susceptible bacteria to control the underlying infection.

What side effects are possible with Kaftrim?

Possible side effects and safety information

The safety profile for Kaftrim (Co-trimoxazole) is systematically organized by regulatory authorities, classifying documented adverse reactions based on frequency and the physiological system affected.

Officially classified side effects commonly affect the gastrointestinal system, often presenting as nausea and diarrhea. Other common effects include headache and certain skin rashes.

Frequency Classification Example Adverse Reaction
Very Common Hyperkalemia (high blood potassium)
Common Nausea, Diarrhea, Headache, Skin rash
Uncommon Vomiting

Serious adverse reactions, though rare, are documented in the regulatory profile. These include life-threatening blood dyscrasias, such as agranulocytosis and aplastic anemia. The profile also includes the official documentation of Severe Cutaneous Adverse Reactions (SCARs), specifically Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The highest risk for these severe skin reactions is documented as occurring within the first weeks of treatment.

Official safety constraints note that the medicine is contraindicated in specific patient populations, including infants less than two months of age and individuals with marked hepatic damage or severe renal insufficiency. Older adults are officially noted as being at a greater risk for certain adverse reactions, including serious skin or blood disorders. Furthermore, adequate fluid intake is specified in the safety information as necessary to prevent the formation of crystals in the urine (crystalluria).

Overdose and Emergency Response

Kaftrim (Co-trimoxazole) overdose is officially documented to present with various acute and chronic manifestations. Acute symptoms often include gastrointestinal distress, such as anorexia, nausea, and vomiting, along with neurological effects like dizziness, confusion, and potential loss of consciousness. The presence of crystalluria (crystals in the urine) or hematuria (blood in the urine) is also a documented sign of overexposure.

Life-threatening outcomes cited in regulatory labeling include severe blood disorders like agranulocytosis and aplastic anemia, fatal reactions such as fulminant hepatic necrosis, and severe skin conditions like Stevens-Johnson Syndrome (SJS). Elevated serum potassium (hyperkalemia) is also a documented risk, which can lead to cardiovascular complications.

The official labeling requires specific immediate action for any suspected overdose. Immediate medical help is required if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Treatment described in regulatory documents is primarily symptomatic and supportive, and may include procedures like gastric lavage and forced fluid administration to promote drug elimination. For chronic toxicity, the administration of Leucovorin (folinic acid) is a listed measure to mitigate the trimethoprim component's effect on the bone marrow. Special consideration is noted for elderly patients, who are more susceptible to severe reactions due to underlying organ impairment.

Therapeutic Uses of Kaftrim

Kaftrim is a fixed-dose antimicrobial combination that provides supportive relief for managing the symptoms and addressing conditions involving inflammatory or irritative processes. It is generally applied across domains where additional symptomatic support is needed to ease the overall burden of acute illness. This combination is commonly used to treat conditions characterized by periods of heightened symptoms.

The medicine is commonly used to help with acute symptomatic episodes such as urinary tract infections (UTIs), specific forms of acute otitis media (middle ear infection), acute flare-ups of chronic bronchitis, and severe forms of diarrhea like shigellosis or Traveler's Diarrhea. Furthermore, it is considered relevant for the treatment and prophylaxis of severe opportunistic infections like Pneumocystis jirovecii pneumonia (PJP) in high-risk patients.

The medicine is generally applied in addressing symptom clusters that may become intense or disruptive, such as the painful urination and urgency of a UTI, or the acute gastrointestinal distress of shigellosis. This approach supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Acute Discomfort

Quick Fact: Relief for Acute Discomfort and Systemic Imbalance

Regulatory References

  1. MedlinePlus overview

Eligibility and Restrictions for Use

Kaftrim's use is strictly defined by regulatory guidelines concerning patient status, age, and pre-existing conditions.

Contraindicated Populations

The medicine is contraindicated (must not be used) in patients with a known hypersensitivity to trimethoprim or sulfonamides, and in patients with documented megaloblastic anemia due to folate deficiency.

Usage is also prohibited for pregnant patients and nursing mothers, and in infants less than 2 months of age. Patients with marked hepatic damage or severe renal insufficiency where function cannot be monitored are also excluded from use.

Age Eligibility
Approved: Adults and children ge 2 months
Contraindicated: Infants < 2 months

Conditional Use and Restrictions

Use is restricted for patients with impaired renal function. For a creatinine clearance (CrCl) between 15 and 30 mL/min, use is conditional and requires a reduced regimen. Use is not recommended when the CrCl is below 15 mL/min. Caution is advised for older adults and individuals with conditions like G6PD deficiency or risk of acute porphyria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Kaftrim's official interaction profile details specific restrictions and mechanisms that affect co-administered substances. Regulatory documentation formally prohibits the combination of Kaftrim (Sulfamethoxazole/Trimethoprim) with Dofetilide due to a documented risk of increased Dofetilide plasma levels, which can lead to severe ventricular arrhythmias. Co-administration with Methanamine is also restricted due to the potential for crystalluria. High-dose Pyrimethamine (exceeding 25 mg weekly) is prohibited due to the additive risk of megaloblastic anemia.

The medicine is documented to alter the exposure of other drugs primarily through pharmacokinetic mechanisms. The Sulfamethoxazole component is an inhibitor of the CYP2C9 enzyme, which can potentiate the anticoagulant effect of Warfarin and prolong the half-life of Phenytoin. The Trimethoprim component inhibits renal transporters (OCT2), resulting in reduced clearance and increased plasma concentrations of drugs like Metformin and Amantadine.

Pharmacodynamic interactions are also documented. Co-administration with ACE Inhibitors or Potassium-sparing Diuretics is associated with an elevated risk of hyperkalemia due to Trimethoprim’s potassium-sparing effect. Furthermore, the product label notes that alcohol (ethanol) use is restricted due to a risk of a documented disulfiram-like reaction.

Mechanism of Action

Kaftrim (Co-trimoxazole) functions via a sequential blockade against bacterial metabolic pathways, specifically targeting the necessary steps for synthesizing genetic material. The dual mechanism begins with the first component, Sulfamethoxazole, which acts as a competitive inhibitor of the enzyme Dihydropteroate synthase (DHPS). This prevents the formation of dihydrofolic acid (FH2). Simultaneously, the second component, Trimethoprim, acts as an inhibitor of Dihydrofolate reductase (DHFR). This dual targeting of two consecutive steps within the same essential pathway generates a synergistic effect.

The resulting failure to generate tetrahydrofolic acid (FH4) causes an immediate and irreversible halt to the mechanistic cascade required for cellular replication and growth. Since FH4 is a necessary coenzyme for the de novo synthesis of purine and pyrimidine nucleotides, the bacterial cell becomes unable to produce new DNA, RNA, or essential proteins. This complete metabolic shutdown results in a bactericidal effect, which causes the death of the susceptible bacterial cells.

Dosage and Administration Information

Kaftrim (Co-trimoxazole) is administered through two primary, officially approved pathways: the oral route via tablet or suspension, and the intravenous infusion (IV) route for severe systemic infections. The general usage principle is defined by standardized dosing and frequency based on the intended regimen. For typical acute infections, the standard adult dose is the Double Strength (DS) tablet, 800 mg SMX / 160 mg TMP, taken twice daily (every 12 hours). Conversely, specific severe infections require a higher, weight-based dosing regimen, often administered up to four times daily.

The duration of use typically ranges from a short course of 5 days for some acute illnesses to an extended course of 14 to 21 days for severe systemic infections. Prophylaxis may be maintained on a once-daily schedule for an indefinite period.

Procedural instructions define how the medicine is taken. Oral doses are taken with a full glass of water. The intravenous concentrate requires mandatory dilution and is delivered as an infusion over 60 to 90 minutes, not as a rapid injection. Dosage adjustments are also required: the regimen is halved for adult patients with a Creatinine Clearance (CrCl) between 15 and 30 mL/min, and the medicine is not recommended for infants younger than 2 months. If a dose is missed, it is taken as soon as possible, unless the next scheduled dose is almost due, and doses are not doubled.

Recent Clinical Evidence

Research evidence / Overview of Studies for Kaftrim (Co-trimoxazole)


Evidence for Use in Treating and Preventing PJP

The use of Kaftrim for treating and preventing Pneumocystis Jirovecii Pneumonia (PJP) has been the subject of extensive research, given that PJP is a serious opportunistic infection. Researchers have conducted numerous Randomized Controlled Trials (RCTs) and long-term observational cohort studies to understand the drug's application, primarily examining patient survival and the rate of new PJP occurrences. Findings from this foundational research contribute to the body of evidence surrounding this combination's use in specific contexts for PJP.

While studies are historically concentrated in the HIV/AIDS population, research highlights that data for the PJP risk in other, newer immunocompromised patient groups remains limited or still emerging. Ongoing research explores dose reduction strategies, indicating that tolerability and dosage optimization remains an area of continued study.


Evidence for Use in Treating Urinary Tract Infections (UTIs)

Kaftrim was evaluated in short-term Randomized Controlled Trials and systematic reviews for both uncomplicated and complicated UTIs. Research examined different treatment courses and compared the combination with other antibiotics. The primary outcomes studied included microbiological eradication (clearance of the target bacteria) and clinical cure (resolution of acute urinary symptoms).

The trials consistently reported that the drug was studied in comparison to other initial treatment options where the causative bacteria are known to be susceptible. However, research highlights the growing global resistance of common UTI-causing bacteria, which limits the applicability of older efficacy data. While long-term data for preventing recurrence are available, guidelines and research must account for regional resistance fluctuations.

Key Studies & References

  1. The Efficacy of Cotrimoxazole for the Prevention of Pneumocystis jirovecii Pneumonia Among HIV-Exposed and Infected Children: A Systematic Review
  2. Natural history of uncomplicated urinary tract infection without antibiotics: a systematic review
  3. Bacterial susceptibility patterns to cotrimoxazole in urinary tract infections of outpatients and inpatients in Jakarta, Indonesia
  4. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)

Frequently Asked Questions (FAQ)

Common questions about Kaftrim (FAQ)


Q: How quickly does Kaftrim start working after you take it?

A: Kaftrim is absorbed rapidly after taking an oral dose. Official pharmacokinetic information indicates that the concentration of the medicine in your bloodstream typically reaches its maximum level within 1 to 4 hours.

Q: Can you take Kaftrim with regular pain relievers like Tylenol or Advil?

A: Official regulatory information does not list common pain relievers like Acetaminophen (Tylenol) or Ibuprofen (Advil) as prohibited combinations. However, because Kaftrim has many documented interactions, regulatory documents recommend consulting a healthcare provider regarding all concurrent medications and supplements.

Q: Is it normal to feel a bit nauseous when you first start Kaftrim?

A: Yes, it is common to experience some gastrointestinal side effects when starting this medicine. Nausea is specifically listed in the official safety profile as one of the most frequently reported adverse reactions.

Q: How long does Kaftrim stay in your system?

A: The medicine is gradually eliminated from the body. The half-life of the sulfamethoxazole component is approximately 10 hours. Official information indicates that clearance time may be significantly longer in individuals with impaired kidney function.

Q: Can Kaftrim affect your sleep?

A: Official regulatory documents indicate that Kaftrim may have neurological side effects. Insomnia (trouble sleeping) is a possible adverse reaction. Other central nervous system effects, such as headache and fatigue, are also documented.

Q: What kind of interactions should I watch out for with Kaftrim?

A: Kaftrim interacts with several types of medications, and official labeling lists many restrictions. Official labeling advises caution when this medicine is co-administered with blood thinners (like Warfarin), certain drugs for diabetes (like Metformin), some heart rhythm medicines, and diuretics that can affect potassium levels.

Q: What happens if you miss a dose of Kaftrim?

A: Official guidance for a missed dose suggests taking it as soon as possible, unless the next scheduled dose is almost due. The guidance also states that doses should not be doubled to make up for the missed one.

Q: Does Kaftrim interact with blood pressure medications?

A: Yes, an interaction with certain blood pressure medicines is documented. Taking Kaftrim with ACE inhibitors, a common class of medication for blood pressure, can elevate the risk of developing hyperkalemia (high blood potassium levels).

Q: What are the signs that Kaftrim is actually working?

A: From a clinical perspective, the effectiveness of Kaftrim is measured by clinical cure, which is the resolution of infection symptoms. It is also assessed by microbiological eradication, meaning the target bacteria have been successfully cleared from the body.

Q: Can Kaftrim cause a rash, and is that serious?

A: Skin rash is listed as a common side effect, and many rashes are mild. However, the regulatory profile warns that Kaftrim carries a rare but documented risk of Severe Cutaneous Adverse Reactions (SCARs). Serious adverse reactions involving the skin are documented in the safety profile and warrant prompt discussion with a healthcare provider.

Q: Do I need to take Kaftrim with food?

A: The tablets can generally be taken either with or without a meal. However, the oral dose should always be taken with a full glass of water, which is specified in the safety information to help prevent crystalluria (the formation of crystals in the urine).

Q: Is it true that Kaftrim can affect your blood sugar levels?

A: Yes, official safety information documents that Kaftrim can cause hypoglycemia (low blood sugar) as an adverse reaction. Furthermore, it is known to increase the effect of some oral medications used to treat diabetes.

Q: What is the difference between Kaftrim and other similar-sounding drugs?

A: Kaftrim is a trade name for the fixed-dose combination product Co-trimoxazole. This means it contains the exact same active ingredients, Sulfamethoxazole and Trimethoprim, as other well-known brands like Bactrim and Septra.

Q: Does Kaftrim make you sensitive to the sun?

A: Yes, the medicine is known to increase your skin’s sensitivity to sunlight, a condition called photosensitivity. Official patient guidance discusses limiting sun exposure and using protective measures like sunscreen and clothing due to this risk.

Q: Can Kaftrim be used for infections other than UTIs?

A: Yes. Beyond urinary tract infections, the medicine is officially approved to treat various other bacterial infections. These indications include certain types of pneumonia, ear infections, and some infections within the gastrointestinal system.

Q: Can Kaftrim cause dizziness or fatigue?

A: Yes, the official safety profile documents that both dizziness and fatigue are possible adverse reactions. These effects are classified under the neurological and general disorder sections of the drug's safety information.

Q: Why do some people say they get a headache from Kaftrim?

A: Headache is a commonly reported adverse reaction listed in the official safety profile. For many patients, a headache is one of the more frequent side effects experienced while taking this medicine.

Q: Is there a risk of allergic reaction to Kaftrim?

A: Yes, there is a risk of allergic reaction, and the medicine is contraindicated (should not be used) if you have a known history of hypersensitivity to its ingredients. Cases of serious, life-threatening allergic reactions (anaphylaxis) have been officially documented.

Q: How does Kaftrim compare to Bactrim?

A: Kaftrim is essentially the same as Bactrim. Both are trade names for the combination of Sulfamethoxazole and Trimethoprim, making them chemically and therapeutically equivalent in their active formulation.

Q: Does taking Kaftrim affect birth control effectiveness?

A: Current official guidelines generally state that this medicine does not significantly reduce the effectiveness of combined hormonal contraceptives (like the pill). Patients are generally advised to consult a healthcare provider for guidance on their specific contraceptive method.

Q: What's the difference between the pill and liquid form of Kaftrim?

A: Both the pill (tablet) and liquid (oral suspension) contain the same active medicinal ingredients. The liquid form is typically used for patients who have difficulty swallowing pills, such as children, or when specific, smaller doses are required.

Q: Is Kaftrim ever used as a preventative medication?

A: Yes. The official indications include the prophylaxis (prevention) of certain opportunistic infections, such as Pneumocystis Jirovecii Pneumonia (PJP), which typically involves a long-term, low-dose regimen.

Q: What are the long-term side effects that have been observed with Kaftrim?

A: For patients on prolonged therapy, the regulatory documentation highlights the risk of serious side effects, particularly blood disorders, such as aplastic anemia. Regulatory documents note that prolonged therapy may necessitate regular blood count monitoring.

Q: Does Kaftrim have any mood-related side effects?

A: Yes. The official safety profile documents psychiatric adverse reactions, including reports of depression and hallucinations. Changes in mood or behavior are adverse reactions that may warrant discussion with a healthcare provider.

Q: Can taking Kaftrim cause changes in appetite?

A: Yes, loss of appetite, medically referred to as anorexia, is documented as a common adverse reaction associated with the gastrointestinal side effects of this medicine.

Q: Are there any foods or drinks you should avoid while on Kaftrim?

A: Regulatory information specifically restricts the use of alcohol (ethanol) while taking Kaftrim due to the risk of a disulfiram-like reaction. The risk of hyperkalemia (high blood potassium) suggests caution regarding the intake of high-potassium foods and supplements.

How should Kaftrim be stored and disposed of?

How to Store and Dispose of Kaftrim (Sulfamethoxazole and Trimethoprim)

Official regulatory guidelines mandate specific storage conditions to maintain the stability and effectiveness of Kaftrim.


Storage Requirements

Formulation Temperature Requirement Protection Requirements
Tablets / Oral Suspension Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) Protect from light and moisture; keep in a tight, light-resistant container
IV Solution Store below 30 C (concentrate) Do not freeze the concentrate or refrigerate the diluted solution

All forms of the medicine must be kept out of the reach of children. The diluted IV solution has limited stability and must be used within hours of preparation, as specified in the labeling. Unused or expired Kaftrim must be disposed of safely by following the official guidelines for the disposal of unused medicines, as directed by local regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kaftrim found in:

A-Z Index: